Blinding in Surgical Trials: Why "Double-Blind" Rarely Means What It Means in Drug Trials

Read the methods section of almost any published drug trial and the phrase "double-blind" is doing a lot of quiet work. It tells a reader that neither the patient taking the capsule nor the physician prescribing it could distinguish active treatment from placebo, and that this held for the length of the study. Read the methods section of a surgical trial and the same phrase often appears, but it cannot be doing the same job. The surgeon making the incision knows which incision they are making. What varies, procedure to procedure, is which other party in the room does not.

What "double-blind" was built to describe

In a pharmaceutical trial, blinding is largely a manufacturing problem. Two capsules, matched for size, color, weight, and taste, are assigned by random allocation, and neither the patient nor, in a fully blinded design, the prescribing physician can tell which is which by looking at it. That is what "double-blind" was coined to describe: two specific parties, both unable to distinguish active treatment from control, for the duration of exposure.

Even there, the term is looser than it sounds. Lang and Stroup, writing in Trials, found that "double-blind" and its relatives (single-blind, triple-blind, "fully blinded") have no standard, widely accepted definition; agreement about exactly which parties a given trial's blinding covers is poor even among readers of the same paper; and authors frequently use the terms without stating who, specifically, was kept unaware of allocation.¹ If the label is already ambiguous in a field where blinding is comparatively easy, it travels badly into a field where it is often close to impossible.

Why the operating room breaks the analogy

A surgical intervention is not a capsule that can be manufactured to resemble its comparator. It is a sequence of actions carried out by a named person who is, by definition, present and participating. In a trial comparing two surgical techniques, or a new approach against a standard one, the operating surgeon knows, in real time, which procedure they are performing. There is no equivalent of the identical pill for the person holding the instrument.

A review of the evidence on blinding across general and abdominal surgery trials, led by Probst and colleagues, concluded that blinding the operating surgeon is essentially unachievable in technique-versus-technique comparisons, while blinding elsewhere in the trial is often attainable and, in practice, inconsistently attempted.² The patient can sometimes be blinded, through matched wound dressings, standardized draping, controlled disclosure of information, or, for a subset of less invasive procedures, a sham incision. The outcome assessor, the clinician or researcher scoring recovery, reviewing imaging, or grading a complication, does not need to have set foot in the operating room, and can often be kept unaware of which arm a given patient was allocated to. Ward staff providing postoperative care can sometimes be blinded as well.

The practical result is that a well designed surgical trial typically blinds a different combination of people than a drug trial does, and usually fewer of them. Filing that arrangement under a term built to describe two blinded parties in a pill trial hides exactly the information a reader needs: which specific safeguard against bias was in place, and which was not.

What actually rides on getting this right

This is not only a labeling problem. A combined analysis of meta-epidemiological studies spanning 1973 trials found that inadequate or unclear double-blinding was associated with an average 13% exaggeration of intervention effect estimates, and that this exaggeration was concentrated almost entirely in trials with subjective outcomes (pain scores, patient-reported function, satisfaction) rather than objective ones such as mortality or reoperation.³ That split maps directly onto surgery. If the surgeon can never be blinded but the outcome assessor can, then how carefully that one safeguard was maintained does a disproportionate share of the work protecting a subjective endpoint from bias, independent of anything the surgeon knew walking into the case.

The CONSORT 2010 statement, the reporting standard adopted by essentially every general and specialty surgical journal, reflects this directly. Rather than asking authors to classify a trial as single-, double-, or triple-blind, it asks them to state whether blinding was used and, if so, who specifically was kept unaware of group assignment: participants, care providers, or those assessing outcomes.⁴ The IDEAL framework for surgical innovation extends the same logic across the life of a surgical evaluation: the trial design appropriate to an early exploratory stage differs from the design appropriate to a confirmatory randomized trial, and at every stage the framework calls for stating plainly which forms of blinding are and are not feasible, rather than importing a template built for a different kind of intervention.⁵

The same specificity matters again after publication

That same specificity matters again well after this paper is in print. When a systematic review of surgical techniques is conducted under PRISMA 2020 guidelines, the recommended tool for judging each included trial's risk of bias, RoB 2, does not have a single "blinding" checkbox either: it scores blinding of participants and personnel separately from blinding of outcome assessors, exactly the same split this article has been making.⁶⁷ A trial that reports "single-blind" without saying who, specifically, leaves a future reviewer guessing at which domain to score and how, often defaulting to "unclear risk" rather than crediting the safeguard that was actually in place. The sentence that protects a reader of this paper is the same sentence that protects this paper's own classification the next time it gets pooled into a meta-analysis.

The fix costs one extra sentence. Name the parties who did not know the allocation, and name the ones who did. "The outcome assessor was unaware of treatment allocation; the operating surgeon and patient were not" tells a reviewer, and a reader downstream, exactly what protection the trial had. "Single-blind" does not.

References

1. Lang TA, Stroup DF. Who knew? The misleading specificity of "double-blind" and what to do about it. Trials. 2020;21:697. https://doi.org/10.1186/s13063-020-04607-5
2. Probst P, Heger P, Zaschke S, Knebel P, Ulrich A, Büchler MW, Diener MK. Evidence-based recommendations for blinding in surgical trials. Langenbecks Archives of Surgery. 2019;404(3):273-284. https://doi.org/10.1007/s00423-019-01761-6
3. Savović J, Jones HE, Altman DG, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine. 2012;157(6):429-438. https://doi.org/10.7326/0003-4819-157-6-201209180-00537
4. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. https://doi.org/10.1136/bmj.c332
5. McCulloch P, Altman DG, Campbell WB, et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374(9695):1105-1112. https://doi.org/10.1016/S0140-6736(09)61116-8
6. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
7. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898